29.62
Kymera Therapeutics Inc stock is traded at $29.62, with a volume of 357.09K.
It is down -1.92% in the last 24 hours and down -2.08% over the past month.
See More
Previous Close:
$30.20
Open:
$30.28
24h Volume:
357.09K
Relative Volume:
0.66
Market Cap:
$1.96B
Revenue:
$87.56M
Net Income/Loss:
$-167.47M
P/E Ratio:
-12.66
EPS:
-2.34
Net Cash Flow:
$-148.20M
1W Performance:
-8.97%
1M Performance:
-2.08%
6M Performance:
-39.17%
1Y Performance:
-26.32%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
KYMR
Kymera Therapeutics Inc
|
29.62 | 1.96B | 87.56M | -167.47M | -148.20M | -2.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-13-25 | Initiated | Citigroup | Buy |
Dec-10-24 | Initiated | BTIG Research | Buy |
Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Nov-18-24 | Initiated | Stephens | Overweight |
Sep-09-24 | Resumed | Leerink Partners | Outperform |
Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Apr-22-24 | Initiated | Oppenheimer | Outperform |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jun-30-23 | Initiated | Truist | Buy |
May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Nov-08-22 | Initiated | Raymond James | Mkt Perform |
Aug-15-22 | Initiated | Jefferies | Buy |
Aug-03-22 | Initiated | Goldman | Buy |
Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
Apr-28-22 | Initiated | Credit Suisse | Outperform |
Mar-10-22 | Initiated | JP Morgan | Neutral |
Feb-10-22 | Initiated | Wells Fargo | Overweight |
Sep-30-21 | Initiated | B. Riley Securities | Neutral |
Sep-30-21 | Initiated | Stifel | Buy |
Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
May-21-21 | Initiated | UBS | Buy |
Apr-14-21 | Initiated | Berenberg | Buy |
Dec-04-20 | Initiated | H.C. Wainwright | Buy |
Sep-15-20 | Initiated | BofA Securities | Neutral |
Sep-15-20 | Initiated | Cowen | Outperform |
Sep-15-20 | Initiated | Guggenheim | Buy |
Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq
(KYMR) Technical Pivots with Risk Controls - Stock Traders Daily
Why Kymera Therapeutics’ Stock is Making Waves - TipRanks
Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK
Don't Ignore The Insider Selling In Kymera Therapeutics - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook - Yahoo Finance
What is B. Riley’s Forecast for KYMR FY2025 Earnings? - Defense World
A Guide To The Risks Of Investing In Kymera Therapeutics Inc (KYMR) - Knox Daily
New York State Common Retirement Fund Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Equities Analysts Offer Predictions for KYMR Q1 Earnings - Defense World
Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World
Kymera Therapeutics announces new performance-based stock plan By Investing.com - Investing.com Australia
Kymera Therapeutics COO sells $42,113 in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics’ chief legal officer sells $68,239 in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics CFO sells shares worth $214,219 By Investing.com - Investing.com South Africa
Kymera Therapeutics’ chief medical officer sells shares worth $174,785 By Investing.com - Investing.com Canada
Kymera Therapeutics CFO sells shares worth $214,219 - Investing.com India
Kymera Therapeutics’ chief medical officer sells shares worth $174,785 - Investing.com
Kymera Therapeutics COO sells $42,113 in stock - Investing.com
Kymera Therapeutics announces new performance-based stock plan - Investing.com India
Kymera Therapeutics Grants Performance Stock Units to Executives - TipRanks
Rhumbline Advisers Acquires 1,861 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Q3 Earnings Forecast for KYMR Issued By HC Wainwright - Defense World
Analysts Set Expectations for KYMR Q2 Earnings - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results - MarketBeat
Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 13.9% on Disappointing Earnings - MarketBeat
(KYMR) Trading Signals - Stock Traders Daily
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus - TradingView
Kymera Therapeutics Inc (KYMR) Volatility Hits 9.22%: What Good Investors Need To Be Aware Of - Stocks Register
Kymera Therapeutics stock target cut to $54 by H.C. Wainwright - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript - Insider Monkey
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus.com
Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews - Benzinga
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... By GuruFocus - Investing.com Canada
Kymera Therapeutics (NASDAQ:KYMR) Reaches New 52-Week Low After Earnings Miss - Defense World
Kymera Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Kymera stock hits 52-week low at $29.23 amid market challenges - Investing.com
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):